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Peripheral artery disease (PAD) is a major cause of acute and chronic illness, with extremely poor 
prognosis that remains underdiagnosed and undertreated. Trimethylamine-N-Oxide (TMAO), a gut 
derived metabolite, has been associated with atherosclerotic burden. We determined plasma levels 
of TMAO by mass spectrometry and evaluated their association with PAD severity and prognosis. 262 
symptomatic PAD patients (mean age 70 years, 87% men) categorized in intermittent claudication (IC, 
n = 147) and critical limb ischemia (CLI, n = 115) were followed-up for a mean average of 4 years (min 
1-max 102 months). TMAO levels were increased in CLI compared to IC (P < 0.001). Receiver operating 
characteristic (ROC) curves for severity (CLI) rendered a cutoff of 2.26 µmol/L for TMAO (62% sensitivity, 
76% specificity). Patients with TMAO > 2.26 µmol/L exhibited higher risk of cardiovascular death (sub-
hazard ratios ≥2, P < 0.05) that remained significant after adjustment for confounding factors. TMAO 
levels were associated to disease severity and CV-mortality in our cohort, suggesting an improvement 
of PAD prognosis with the measurement of TMAO. Overall, our results indicate that the intestinal 
bacterial function, together with the activity of key hepatic enzymes for TMA oxidation (FMO3) and 
renal function, should be considered when designing therapeutic strategies to control gut-derived 
metabolites in vascular patients.
Peripheral artery disease (PAD) is a largely unrecognized manifestation of atherosclerotic pathologies and a 
major cause of acute and chronic illness. Its prevalence in Western societies increases with age; 20% of the patients 
over 65 years are diagnosed with PAD, and is associated with exceptionally high risk for myocardial infarction 
(MI), ischemic stroke and death. Given that PAD typically presents in later life, its prevalence will undoubtedly 
escalate in response to changing population demographics and lifestyle1,2. Despite this prospect and its extremely 
poor prognosis, PAD remains undiagnosed and undertreated, highlighting the need for new markers that may 
provide insight into the underlying pathophysiology, improve long-term clinical risk prediction, and suggest 
novel therapeutic targets.
Recent studies have shown a direct link between dietary nutrients, intestinal microbiota, and cardiometabolic 
diseases3,4. In this regard, several human and animal studies have identified trimethylamine N-oxide (TMAO), 
metabolite of the gut microbe-derived trimethylamine (TMA), as a potential promoter of chronic diseases includ-
ing atherosclerosis in humans5–7. TMA is generated by the action of specific microbial enzymes on dietary nutri-
ents (choline, phosphatidylcholine, and L-carnitine), then absorbed by the host and converted into TMAO by 
hepatic flavin monooxygenases (FMO3). Subsequently, TMAO is either transported to the tissues for accumula-
tion as an osmolyte or, more commonly, cleared by the kidney8. In humans circulating TMAO and its precursors 
have been associated with atherosclerotic burden9,10, increased risk for cardiovascular (CV) disease, and Major 
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adverse CV events (MACE) and death in coronary and peripheral arterial diseases5–7,11–14. In preclinical mod-
els TMAO accelerated atherosclerosis development5,11,15, and induced thrombosis12,16, supporting a role for gut 
microbiota in the pathogenesis of atherosclerosis and its associated complications.
Taking in consideration the need of new markers for CV risk evaluation in PAD and the association of TMAO 
with vascular pathologies and worse outcome, we hypothesized that the measurement of TMAO could help to 
assess outcome evaluation in symptomatic PAD patients.
Results
TMAO levels are increased in CLI patients. Table 1 summarizes the demographic and clinical parameters 
of PAD patients (n = 262). First we analysed the association of TMAO with well-established vascular risk factors 
in PAD patients. A positive correlation with age (r = 0.25, p < 0.001) and hs-CRP (r = 0.22, p = 0.001) could be 
demonstrated, while an inverse association was found with ankle brachial index (ABI, r = −0.23, p = 0.001), 
estimated-glomerular filtration rate (eGFR, r = −0.40, p < 0.001), and HDL-C (r = −0.18, p = 0.003). Similarly, 
correlations between TMAO and age (r = 0.307, p = 0.040) and eGFR (r = −0.384, p = 0.009) were also observed 
in a smaller group of people with no manifest CV disease (n = 45, Supplementary Table 2). PAD patients were 
PAD (n = 262) IC n = 147 CLI n = 115 p vs IC
Demographic and clinical data
   Sex (male, %) 87 88 85 0.442
   Age (years) 70 (11) 68 (10) 73 (11) <0.001
   Smokers (%)
     Never 20 12 29 0.004
     Current 32 35 29
     Former 48 53 42
   Diabetes mellitus (%) 53 36 74 <0.001
   Hypertension (%) 74 72 77 0.331
   Dyslipidemia (%) 62 67 57 0.093
   BMI (kg/m2) 28 (5) 28 (5) 28 (6) 0.830
   ABI 0.55 (0.19) 0.62 (0.17) 0.38 (0.13) <0.001
Personal history (%)
   COPD 14 14 13 0.772
   CKD 39 24 58 <0.001
   AMI 28 26 30 0.486
   Cardiomyopathy 25 14 38 <0.001
   Cerebral ischemia 9 5 14 0.009
Treatment (%)
   Anticoagulants 13 8 20 0.005
   Antiplatelets 77 82 70 0.033
   ACE inhibitors 34 32 36 0.440
   ARA-2 27 23 32 0.102
   Calcium antagonists 22 18 27 0.071
   Vasodilators 7 6 8 0.589
   β-Blockers 24 24 23 0.722
   Statins 65 69 59 0.084
Laboratory data
   Total col (mg/mL) 172 (46) 187 (41) 153 (47) <0.001
   LDL-C (mg/dL) 110 (91) 114 (83) 104 (99) 0.360
   HDL-C (mg/dL) 43 (16) 49 (15) 36 (13) <0.001
   Triglycerides (mg/dL) 145 (81) 151 (88) 138 (70) 0.194
   hs-CRPa (mg/mL) 5 (11) 3 (4) 10 (22) <0.001
   AST (U/L) 21 (9) 21 (9) 20 (8) 0.194
   ALT (U/L) 21 (14) 22 (14) 19 (13) 0.081
   GGT (U/L) 54 (69) 50 (61) 60 (78) 0.244
   eGFR (mL/min/1.73 m2) 73 (21) 79 (19) 66 (22) <0.001
Table 1. Demographic and clinical parameters in PAD patients (n = 262). Mean (SD) is shown. aLog-
transformed variables are presented as median (interquartile range). BMI: body mass index, ABI: ankle-brachial 
index, COPD: chronic obstructive pulmonary disease, CKD: chronic kidney disease, AMI: acute myocardial 
infarction, ACE: angiotensin-converting enzyme, ARA-2: angiotensin II receptor antagonist, LDL: low-density 
lipoprotein, HDL: high-density lipoprotein. ALT: alanine aminotransferase; AST: aspartate aminotransferase; 
GGT: gamma glutamyltransferase; GFR: Glomerular filtration rate.
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then categorized according to disease severity (Table 1). Subjects with critical limb ischemia (CLI) were older, 
presented higher percentage of diabetes and chronic kidney disease (CKD), and lower eGFR compared to inter-
mittent claudication (IC). Levels of hepatic enzymes (AST, ALT and GGT) were similar and within usual ranges 
in both groups indicating normal liver function in our cohort. TMAO determination showed increased levels of 
TMAO in CLI subjects compared to IC [median: 1.30(0.83–2.25) IC vs 2.77(1.45–7.16) µmol/L CLI, p < 0.001].
Logistic regression analysis showed and association between TMAO and PAD severity alone (model 1, 
Table 2) and after correcting by other risk factors (model 2, Table 2). The interaction between eGFR and TMAO 
in PAD severity was excluded by logistic regression analysis (p for interaction 0.632).
Receiver operating characteristic (ROC) curves were plotted to assess disease severity (IC vs. CLI) for 
TMAO [AUC: 0.731 ± 0.032 (95% CI: 0.669–0.792) p < 0.001] rendering a cut-off value of >2.26 µmol/L (62% 
sensitivity, 76% specificity), that was latter used to performed similar multivariate analysis. High TMAO levels 
(>2.26 µmol/L, n = 107) presented a significant association with PAD severity alone and after adjusting by other 
covariates (Table 2).
TMAO is associated to CV-mortality in PAD. To evaluate the possible prognostic value of TMAO 
we recorded MACE (n = 135) and mortality, either all-cause (n = 101) or cardiovascular (n = 39) during the 
follow-up (4 years, min 1-max 102 months).
Cox regression analyses for overall mortality were performed before and after covariate adjustment. High 
TMAO concentrations were associated to all-cause mortality in the unadjusted model, but not after correcting by 
traditional risk factors (Supplementary Table 3).
We next determined the prognostic value of TMAO for CV-mortality. High TMAO levels rendered significant 
associations with all tested models (Table 3). Correspondingly, categorized TMAO displayed similar association 
(>2.26 µmol/L, Fig. 1), with sub-hazard ratios above 2 for all tested models, being highest for model 4 (Table 3).
Finally, we determined proportional hazards for TMAO considering MACE (n = 135, 51%). TMAO showed 
no independent association with this outcome in the multivariate Cox analysis (Supplementary Table 3).
To estimate the potential of TMAO to improve CV-death risk prediction over and beyond the basal models 
considered, Harrell’s C, integrated discrimination improvement (IDI) and continuous NRI analyses were per-
formed. The addition of the categorical variable TMAO (>2.26 µmol/L) to the considered models including 
the previously mentioned relevant covariates, improved risk prediction for CV mortality in symptomatic PAD 
patients as assessed by NRI in models 2, 3 and 4 (Table 4).
Discussion
We determined plasma levels of TMAO to assess their association with PAD severity and their possible use 
as prognostic markers in symptomatic PAD. TMAO was independently associated to PAD severity and 
CV-mortality, but not to all-cause death and MACE.
The analysis of circulating gut-microbiome derived products has identified TMAO, a secondary product 
after TMA is metabolized by the liver enzyme FMO3, as a possible prognostic marker in cardiometabolic dis-
eases5–7. In most cases increased levels of TMAO or its initial precursors, betaine, choline or L-carnitine, have 
been associated to atherosclerotic burden5,9,10,17 and worse outcome in arterial pathologies in large cohorts6,7,11–13. 
In addition, the causal role of TMAO in atherosclerosis development has been further studied in murine models, 
TMAO, µmol/La TMAO, cutoff (>2.26 µmol/L)
p ≤2.26 >2.26 p
Model 1 1.84 (1.49–2.27) <0.001 1 4.97 (2.92–8.47) <0.001
Model 2 1.68 (1.3–2.2) <0.001 1 4.4 (2.1–9.1) <0.001
Table 2. Logistic regression analysis to estimate the odds ratio (OR, 95% confidence interval) for TMAO in 
PAD patients (n = 262). Dependent variable IC/CLI. aLog-transformed variable. Unadjusted Model 1. Model 2: 
sex, age, smoking, diabetes mellitus, hypertension, dyslipidemia, HDL-C, eGFR (<60 mL/min/1.73 m2), and hs-
CRP (log-transformed).
TMAO, µmol/La TMAO, cutoff (>2.26 µmol/L)
SHR 95% CI p SHR 95% CI p
CV death
   Model 1 1.52 1.27–1.83 <0.001 3.44 1.74–6.79 <0.001
   Model 2 1.39 1.13–1.70 0.001 2.55 1.22–5.28 0.012
   Model 3 1.29 1.05–1.60 0.015 2.15 1.04–4.48 0.040
   Model 4 1.52 1.27–1.82 <0.001 3.36 1.68–6.70 0.001
Table 3. Association of TMAO (µmol/L) with CV death. aLog-transformed variable. Sub-hazard ratios (SHR) 
are effects sizes for a doubling of TMAO in plasma. Model 1: unadjusted. Model 2: sex, age and hs-CRP (log). 
Model 3: diabetes mellitus, hypertension, and eGFR (<60 mL/min/1.73 m2). Model 4: smoking, dyslipidemia, 
HDL-C.
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showing accelerated plaque development with dietary supplementation of TMAO or its precursors (e.g.: cho-
line, L-carnitine)5,11,15,18,19. Nonetheless, some authors found no predictive value of high TMAO levels for CV 
events or mortality in smaller cohorts of patients with suspected coronary artery disease20 or receiving dialysis21, 
and the contribution of TMAO to early atherosclerosis development in healthy-middle-aged adults is unclear22. 
Symptomatic PAD patients present a complex pathophysiology, frequently associated with comorbidities such as 
diabetes, hypertension, or CKD, that are suspected to greatly interfere with the metabolism of microbial derived 
products8. Indeed, TMAO homeostasis considerably depends on liver FMO3 activity16 and renal clearance8,23. 
We found increased levels of TMAO in CLI patients compared to IC, and also determined hepatic enzymes for 
liver function assessment, finding no differences in transaminases between IC and CLI. Despite these results, we 
cannot exclude increased FMO3 activity in our cohort as no direct measurement of the enzymatic activity was 
performed. Moreover, other factors such as sex hormones, bile acids or insulin have been also described to regu-
late FMO3 activity and increase TMA oxidation24,25.
TMAO accumulation might be also related to worse kidney clearance23, since it has been described that 
patients with decreased kidney function present elevated levels of TMAO in circulation compared to those with-
out CKD21,26–28. A trend for reduced eGFR according to TMAO quartiles was reported in the KarMeN study29, 
while no association of TMAO with creatinine was observed in the EPIC-Heidelberg study30, suggesting an 
Figure 1. TMAO levels are associated to CV-mortality in PAD. Unadjusted cumulative incidence curve for the 
risk of CV mortality after a competing risk analysis (Fine-Gray model), where the competing event was non-CV 
death, in all patients categorized according to the TMAO cutoff (>2.26 µmol/L).
TMAO, cutoff (>2.26 µmol/L)
Value 95% CIa p
Model 2
   Harrell’s C
     Basal model 0.787 0.713 to 0.862
     Basal model + biomarker 0.805 0.737 to 0.873 0.40
   IDI 0.034 −0.002 to 0.104 0.19
   NRI 0.700 0.169 to 0.949 <0.001
Model 3
   Harrell’s C
     Basal model 0.738 0.652 to 0.823
     Basal model + biomarker 0.760 0.681 to 0.840 0.31
   IDI 0.018 −0.006 to 0.074 0.38
   NRI 0.667 0.094 to 0.967 0.003
Model 4
   Harrell’s C
     Basal model 0.629 0.492 to 0.767
     Basal model + biomarker 0.683 0.564 to 0.802 0.16
   IDI 0.035 0.001 to 0.102 0.17
   NRI 0.712 0.362 to 0.953 <0.001
Table 4. Added predictive value of TMAO > 2.26 µmol/L for CV death in PAD patients. Model 2: sex, age 
and hs-CRP (log-transformed). Model 3: diabetes mellitus, hypertension, and eGFR (<60 mL/min/1.73 m2). 
Model 4: smoking, dyslipidemia, HDL-C. IDI, integrated discrimination improvement; NRI, net reclassification 
improvement. aThe variance was calculated using bootstrapping (with 1000 resamples) for the IDI and NRI 
estimates and the jackknife approach for the Harrell’s C estimates.
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irrelevant role of the kidney function for TMAO homeostasis in healthy subjects. In contrast, we found a negative 
correlation between TMAO and eGFR in a small cohort of people with no manifest cardiovascular disease, but 
with more than two cardiovascular risk factors, and older than those in the studies by Krüger et al. and Kühn et 
al.29,30. These data suggest that individuals with mildly impaired kidney function might be more susceptible to the 
detrimental effects of TMAO accumulation. In line with these observations and taking in consideration the high 
percentage of CKD patients in our PAD population (39%), we found a lineal-inverse association between TMAO 
and eGFR, and tested the possible interaction between the two according to disease severity. No interaction 
between TMAO and eGFR was found, however, considering the important role of the kidney on TMAO homeo-
stasis8, eGFR was included as covariate for further regression analysis. To assess the accuracy of TMAO levels for 
PAD patient stratification we established the association between TMAO and PAD severity after adjustment for 
traditional risk factors and described a cutoff value with diagnostic purposes.
Increased levels of plasma TMAO have been shown to predict future major adverse cardiac events includ-
ing myocardial infarction, stroke, and death in different CV pathologies6,7,11,12,31 and a role for gut derived 
metabolites in thrombosis has been described in vivo, showing that intestinal microbes can directly mod-
ulate platelet hyperresponsiveness and clot formation rate via TMAO generation12,16. Even if most studies 
point towards TMAO as marker of worse outcome in CV pathologies, controversy remains when specific 
patient cohorts are evaluated. For example, no correlation between TMAO and increased risk for CV dis-
ease or MACE was observed in a group of end-stage renal disease patients21 and in subject with suspected 
CAD undergoing coronary angiography20. Mueller et al. speculated that those results could be confounded 
at least in part by impaired kidney function or poor metabolic control20 and encouraged the consideration 
of these parameters when interpreting the results. In addition, TMAO has been studied mainly in coronary 
pathologies, while it is prognostic value in other arterial localization, such as PAD, has been little investi-
gated. We report an association between TMAO and CV-mortality, but not with all-cause death or MACE. 
Our results differ in part from previous data, describing an association of TMAO levels and global death in 
PAD14. However, differences between the studied populations regarding PAD definition and severity status 
should be considered when interpreting the data. Senthong et al. included by the term PAD the majority of 
non-coronary arterial territories14, while our cohort is restricted to symptomatic lower limb artery disease 
(mean ABI 0.55 ± 0.19). TMAO appears to be better for CV-mortality prognosis than for all-cause death, 
which might be important for patient evaluation.
Limitations. The current study including 262 patients could be considered as small, however the high per-
centage of deaths (39% all-cause and 15% CV origin) provides the statistical power required to support our con-
clusions. Events were recorded during a mean follow up of 4 years, reasonable to estimate early to medium-term 
mortality. Longer term studies should be designed to confirm the involvement of TMAO in PAD mortality. No 
causal relationship between high TMAO levels and CV-mortality can be inferred from our prospective study. 
Death cause in some patients was unknown and we might have lost some cases related to CV events. Finally, the 
influence of two important variables for TMAO production, the use of antibiotics and modifications in dietary 
habits were not recorded and could not be included as confounding variables in our population. FMO3 activity, 
which has been implicated in thrombosis risk16 and converts TMA in TMAO24, was not measured.
Conclusions. We show increased TMAO levels according to PAD severity and an independent associ-
ation between TMAO and elevated risk for CV-mortality. The design of novel therapeutic strategies towards 
gut-derived metabolite control in vascular patients will need to consider not only intestinal bacterial function, but 
also the activity of key hepatic enzymes for TMA oxidation (FMO3), and renal function.
Methods
The clinical and demographic characteristics of the PAD cohort were previously described by Martinez-Aguilar 
et al.32,33. As the cohort has included new cases we include the complete description in supplemental material and 
methods. Control subjects were previously described by Marcos-Jubilar M et al.34.
Baseline characteristics of PAD and control patients. PAD Patients [n = 262, mean age 70 years (SD: 
11), 87% men] were prospectively enrolled at the outpatient service of the Department of Vascular Surgery of 
Complejo Hospitalario de Navarra between 2010 and 2017 (supplemental information). Blood samples were 
collected at the time of clinical evaluation and tested for biochemical parameters. Ankle brachial index (ABI) was 
measured at rest, in both lower limbs.
Fontaine classification was used for severity assessment as follows: intermittent claudication (IC, Fontaine 
class II, n = 147) diagnosed by hemodynamic study (Doppler ultrasound), and critical limb ischemia (CLI, 
n = 115) with lower limb rest pain and/or trophic lesions (Fontaine class III-IV) confirmed by imaging studies 
(arteriography, magnetic resonance angiography, or ultrasonography). Exclusion criteria were established as fol-
lows: patients with Fontaine class IV and infected-lesions, individuals with evidence of neoplastic disease, gener-
alized or localized inflammatory disease (moderate or severe), severe chronic kidney disease, on haemodialysis, 
or receiving antinflammatory drugs.
Control subjects (n = 45) were enrolled at the outpatient service of the Department of Internal Medicine, 
Clínica Universidad de Navarra (April 2016-December 2017). Blood samples were collected at the time of clinical 
evaluation. Patients were included if older than 45 years, with ≥2 cardiovascular risk factors and no manifested 
cardiovascular disease at recruitment. Exclusion criteria included active neoplastic disease, acute or chronic 
inflammatory disease of any aetiology, and intake of nonsteroidal anti-inflammatory or steroid drugs 2 weeks 
before blood withdrawal. Samples and data from control patients were provided by the Biobank of the University 
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of Navarra and were processed following standard operating procedures approved by the Ethical and Scientific 
Committees.
The study was approved by the Institutional Review Boards of Complejo Hospitalario de Navarra and Clínica 
Universidad de Navarra, according to the standards of the Declaration of Helsinki on medical research, and writ-
ten informed consent was obtained from all patients who were enrolled in this study.
PAD patients were followed up for a mean period of 4 years (min 1 max 102 months) at the outpatient service 
of the Department of Vascular Surgery every 3, 6 or 12 months, depending on the severity of PAD. Death, either 
all-cause or cardiovascular, and MACE including amputation, stroke, myocardial infarction and all-cause death 
were recorded.
TMAO determination. Based on a previously reported approach by Awwad H.M., et al.35, a precise and reli-
able UHPLC-MS/MS method has been implemented in our laboratory for the quantification of TMAO in human 
plasma. Frozen citrate plasma samples, in which the corresponding stabilized TMA salt was formed, were utilized 
to perform these analyses. Concentrations of the analyte in plasma samples was determined from calibration 
curves, which indicated a good linearity (r2 ≥ 0.999) within the studied concentration range (100 nM–10 μM), 
using peak area ratio of the analyte to its isotope. The implemented UHPLC-MS/MS method has good analytical 
accuracy, precision and recovery; in fact, the recoveries ranged between 97% and 104% and, accuracy and pre-
cision of the assays were between 3.7% and 7.3% (reported in the Supplementary Table S1). Details about stand-
ards and chemicals, calibration curve and sample preparation as well as UHPLC and MS system conditions are 
explicitly described in the Supplementary Information together with their corresponding Figures (Supplementary 
Figs S1 and S2).
Statistical analysis. Normality was demonstrated by the Kolmogorov-Smirnov test. Non-normally dis-
tributed variables were log-transformed. Differences between two groups of subjects were tested by Student’s t 
test (normal unpaired data) or Mann-Whitney U test (nonparametric test). χ2 or Fisher’s exact test was used 
for categorical variables. Association studies were performed by Pearson correlation test for continuous varia-
bles. Receiver Operating Characteristic (ROC) curves were plotted to assess disease severity (IC vs. CLI), and 
the cut-off value for TMAO established with the Youden Index. Multivariable logistic regression models were 
adjusted for relevant covariates: age, sex, cigarette smoking, diabetes mellitus, hypertension, dyslipidemia, 
HDL-C, eGFR (<60 mL/min/1.73 m2) and hs-CRP14,32. Multicollinearity was evaluated by the variance infla-
tion factor and models calibrated by the Homer-Lemeshow goodness-of-fit test. Patients without outcome 
were censored at the date of their last follow-up. Hazard ratios (HR) and their 95% CI for death (all-cause) 
and MACE were estimated using Cox regression models after adjusting for relevant covariates. Fine-Gray 
competing risk models were used to obtain sub-hazard ratios for CV death, considering non-CV death as a 
competing event. Due to the low number of CV death events, the following basal models were considered for 
adjustment for relevant covariables: model 1, unadjusted; model 2, sex and hsCRP (log); model 3, diabetes 
mellitus, hypertension and eGFR (<60 mL/min/1.73 m2); model 4, smoking, dyslipidemia and HDL-C. The 
additional value of TMAO for risk prediction of CV death was assessed with Harrell’s C statistics and the con-
tinuous net reclassification index (NRI) index. Values are expressed as mean ± SD or median (interquartile 
range), and categorical variables as numbers and percentages. Analyses were performed with STATA version 
12 (Stata Corp., College Station, TX, USA) and SPSS version 15. All p-values are two-tailed, and statistical 
significance was set at p < 0.05.
Data availability
The datasets generated during and/or analysed during the current study are available from the corresponding 
author on reasonable request.
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